AbbVie’s 2Q previews future growth drivers

New sales figures from AbbVie's 2Q19 earnings report gave investors a glimpse into the launch trajectories of drugs the pharma is relying upon to replace lost sales of Humira after the blockbuster begins to face U.S. biosimilar competition in 2023.

Despite global sales of Humira adalimumab falling 4.8% at constant currency rates to $4.9 billion this quarter compared with 2Q18, AbbVie Inc. (NYSE:ABBV) upped its 2019 guidance on the back of higher-than-expected sales of one of its planned Humira successors...